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ABSTRACT
Background: Non-alcoholic fatty liver disease (NAFLD) is recognised as one of the most important causes 
of chronic liver disease and has become an important health issue in many countries. The aim of the study was 
to evaluate the prevalence and risk factors of NAFLD patients based on ultrasound diagnosed in medical check 
up setting.
Method: In this study, of 2,105 patients undergoing medical check up in Charitas Hospital, Palembang 
between January 2011 to August 2013, 115 NAFLD patients and 113 non-NAFLD patients as controls were 
included. Diagnosis of NAFLD was based on ultrasound appearance, patients did not consume alcohol, with 
negative HBsAg and hepatitis C virus antibodies.
Results: The prevalence of NAFLD in medical check up patients was 7.9% whereas 39% patients had normal 
body mass index (BMI) (< 25 kg/m2). Patients with NAFLD compared with non-NAFLD patients had higher 
values of BMI (p < 0.001), triglycerides (p = 0.001), aspartate aminostransferase (AST) (p < 0.001), alanine 
aminotransferase (ALT) (p < 0.001), fasting glucose (p = 0.002), and lower HDL cholesterol (p = 0.001). Obesity 
was the strongest associated factor for NAFLD (95% CI = 1.87-7.85; OR = 3.83; p < 0.001), followed by high 
glucose levels (95% CI = 1.38 - 8.31; OR = 3.83; p = 0.008) and hypertriglyceridemia (95% CI = 1.38 - 4.11; 
OR = 2.38; p = 0.002).
Conclusion: About 7.9% patients suffered from NAFLD. Approximately 39% medical check up patients had 
NAFLD with normal BMI. Obesity, hypertriglyceridemia and high glucose levels were the risk factors for NAFLD.
Keywords: non-alcoholic liver disease, body mass index, prevalence, metabolic syndrome
ABSTRAK 
Latar belakang: Penyakit perlemakan hati non alkoholik (PPHNA) merupakan salah satu penyebab terpenting 
penyakit hati kronis dan telah menjadi masalah kesehatan di berbagai negara. Tujuan dari penelitian ini adalah 
untuk mengetahui prevalensi dan faktor risiko PPHNA yang didiagnosis berdasarkan pemeriksaan ultrasonografi 
pada pemeriksaan medical check up (MCU).
Metode: Dalam penelitian ini, dari 2.015 pasien yang menjalani MCU di Rumah Sakit Charitas, Palembang 
selama periode Januari 2011 hingga Agustus 2013, dilibatkan sejumlah 115 pasien penderita PPHNA dan 113 
pasien non-PPHNA sebagai pembanding. Diagnosis PPHNA berdasarkan pada pemeriksaan ultrasonografi, 
pasien bukan peminum alkohol, HBsAg dan anti hepatitis C virus negatif.
Hasil: Angka prevalensi PPHNA adalah 7,9% dimana sejumlah 39% pasien PPHNA memiliki indeks massa 
tubuh normal (25 kg/m2). Pasien dengan PPHNA dibandingkan yang pasien non-PPHNA mempunyai nilai 
lebih tinggi secara bermakna pada indeks massa tubuh (p < 0,001), kadar trigliserida (p = 0,001), aspartate 
aminotransferase (AST) (p < 0,001), alanin aminotranferase (ALT) (p < 0,001), gula darah puasa (p = 0,002), 
dan memiliki kadar kolesterol HDL lebih rendah (p = 0,001). Obesitas merupakan faktor risiko terkuat terjadinya 
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PPHNA (95% CI = 1,87–7,85; OR = 3,83; p < 0,001), diikuti peningkatan kadar glukosa (95% CI = 1,38–8,3; 
OR = 3,83; p = 0.008) dan hipertrigliseridemia (95% CI = 1,38–4,11; OR = 2,38; p = 0,002).
Simpulan: Prevalensi pasien dengan PPHNA adalah 7,9%. Sejumlah 39% pasien PPHNA mempunyai 
indeks massa tubuh normal. Obesitas, hipertrigliseridemia dan kadar gula darah tinggi merupakan faktor risiko 
terhadap PPHNA. 
Kata kunci: penyakit perlemakan hati non alkoholik, indeks massa tubuh, prevalensi, sindrom metabolik.
INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is the 
hepatic pandemic of the 21st century, being the number one 
cause of chronic hepatic disease in the occidental world. 
Although usually benign, fatty liver may be associated 
with serious injury, inflammation and hepatocyte necro-
apoptosis, non-alcoholic steatohepatitis (NASH) in 20–
30% of subjects. Those patients are at risk of developing 
fibrosis, with one fifth progressing to liver cirrhosis.1 The 
definition of non-alcoholic fatty liver disease (NAFLD) 
requires: (a) presence of evidence of hepatic steatosis, 
either by imaging or histology, and (b) absence of causes 
for secondary hepatic fat accumulation such as significant 
alcohol consumption, use of steatogenic medication, or 
hereditary disorders. In the majority of patients, NAFLD 
is associated with metabolic risk factors such as obesity, 
diabetes mellitus, and dyslipidemia.2 
Histologically, NAFLD is further catagorized into 
non-alcoholic fatty liver  which there is the presence 
of hepatic steatosis with no evidence of hepatocellular 
injury in the form of ballooning of the hepatocytes, 
and non-alcoholic steatohepatitis (NASH). NASH 
is defined as the presence of hepatic steatosis and 
inflammation with hepatocyte injury (ballooning) 
with or without fibrosis.1,2 The prevalence of NAFLD 
in adults is about 20% and the prevalence of NASH 
is 2-5%.3
The diagnosis of NAFLD requires a combination 
of invasive and non-invasive test. Liver biopsy 
is considered the gold standard for definitive 
diagnosis of NAFLD. The most frequent and readily 
available method to measure hepatic steatosis is 
by ultrasonography (USG). The overall sensitivity, 
specificity, positive likelihood ratio, and negative 
likelihood ratio of ultrasound for the detection of 
moderate-severe fatty liver, compared to histology 
(gold standard) were 84.8%, 93.6%, 13.3 and 0.16, 
respectively.4 The aim of the study was to evaluate 
the prevalence and risk factors of NAFLD patients 
based on ultrasound diagnosed in medical check 
up setting.
METHOD
From January 2011 to August 2013, there were 
2,105 patients undergoing medical check up in Charitas 
Hospital, Palembang. Sociodemographic characteristics 
(age and sex), medical history (alcohol consumption, 
smoking habits, past history of chronic liver disease, 
hypertension, stroke, diabetes mellitus, coronary 
arterial disease), anthropometric measurement (weight, 
height, body mass index (BMI), blood pressure) and 
laboratory data (blood sugar, total cholesterol, high 
density lipoprotein (HDL)-cholesterol, low density 
lipoprotein (LDL)-cholesterol, triglycerides, alanine 
aminotransferase (ALT), aspartate aminotransferase 
(AST), hepatitis B surface antigen (HBsAg) and anti-
hepatitis C virus (HCV) were recorded.
The abdominal ultrasonography was performed, 
and the presence of fatty liver was defined as the 
increased echogenicity of the hepatic parenchyma 
(longitudinal sonogram of the right lobe of the liver 
and right kidney shows increased overall echogenicity 
of the liver) and posterior attenuation.5 Each patient 
was submitted to an abdominal ultrasound examination 
with Aloka Model SSD-3500 Prosound, using 3.5 
MHz convex probe. National Institute of Health 
defined BMI was considered as obesity (BMI ≥ 30 
kg/m2), overweight (BMI 25-29.9 kg/m2) and normal 
(BMI < 25 kg/m2).6 Metabolic syndrome was defined 
according to the criteria of the National Cholesterol 
Education Program: Adult Treatment Panel III.7 In 
particular, patients were considered to have metabolic 
syndrome, if they met three or more of the following 
criteria: (1) increased waist circumference > 102 cm 
for males or > 88 cm for females; (2) high triglyceride 
levels ≥ 150 mg/dL; (3) low HDL cholesterol < 40 
mg/dL for males and ≥ 150 mg/dL for females; (4) 
fasting plasma glucose ≥ 110 mg/dL or previously 
diagnosed type 2 diabetes mellitus; (5) elevated arterial 
pressure: systolic ≥ 135 mmHg and/or diastolic ≥ 85 
mmHg or previously diagnosed hypertension. Waist 
circumference examination was not routinely done in 
Charitas Hospital, so this parameter was replaced by 
BMI > 30 kg/m2.
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Adults of both sexes from the Charitas Hospital who 
came to the hospital for medical check up, between the 
ages 15–80 years old who had been confirmed to have 
fatty liver by ultrasonography were included. Patients 
were not included in the study if they had history of 
alcohol intake, presence of chronic liver disease, presence 
of the HBsAg or the presence of HCV antibodies.
Quantitative data were expressed as mean values 
± standard deviation. The normality of distribution 
of continuous quantitative variables was tested using 
the Kolmogorov-Smirnov test. Comparisons between 
groups of quantitative variables with normal or 
abnormal distribution were performed using T-test 
or Mann-Whitney test, respectively. Comparison of 
categorical or prevalence were performed using Chi-
square test. A two tailed p < 0.05 was considered to 
be statically significant. All analysis was carried out 
using the SPSS 17.0.
RESULTS
From January 2011 to August 2013, there were 
2,105 patients undergoing medical check up in Charitas 
Hospital, Palembang. Based on liver ultrasound, there 
were 166 (7.9%) patients diagnosed as NAFLD, but 
only 115 patients were included in this study because of 
missing data and 113 patients with normal ultrasound 
(non–NAFLD) were recruited as control.
The majority (81.1%) of the patients was male, 
which was more common to suffer from NAFLD 
than female patients. The average age of the NAFLD 
patients were 43.38 ± 9.26 year old and NAFLD 
patients were older than non-NAFLD patients (p = 
0.005). 
Patients with NAFLD compared with non-NAFLD 
patients had higher values of BMI (27.72 ± 4.61 vs. 
24.92 ± 4.02; p < 0.001), triglycerides (170 ± 101 mg/
dL vs. 128 ± 84 mg/dL; p = 0.001), AST (27.35 ± 10.06 
IU/L vs. 22.52 ± 9.90 IU/L; p < 0.001), ALT (45.45 ± 
24.11 IU/L vs. 29.92 ± 42.66 IU/L; p < 0.001), fasting 
glucose (101.64 ± 31.33 mg/dL vs. 91.68 ± 22.90 mg/
dL; p = 0.002), and had lower HDL cholesterol (47.29 
± 18.50 mg/dL vs. 52.15 ± 14.52 mg/dL; p = 0.001) 
(Table 1). In this study, ALT and AST levels increased 
in 34.7 % and 9.6% of NAFLD patients, respectively.
The prevalence of the metabolic syndrome according 
to presence of NAFLD and BMI criteria was shown 
in Table 2 and 3. According to metabolic syndrome 
criteria, NAFLD patients compared to non-NAFLD 
patients were more obese (31.30 % vs. 10.62 %; p 
Table 1. Clinical and laboratory data of the patients
Characteristics Total
n (%)
Non-NFALD
n (%)
NFALD
n (%) p 
Sex
Male 185 (81.1%) 85 (75.2%) 100 (87 %) 0.028
Female 43 (18.9%) 28 (24.8%) 15 (13 %)
Age (years) 41.57 ± 9.76 39.73 ± 9.94 43.38 ± 9.26 0.005
BMI (kg/m2) 26.33 ± 4.54 24.92 ± 4.02 27.72 ± 4.61 < 0.001
SBP (mmHg) 119.30 ± 13.02 118.63 ± 12.87 119.96 ± 13.19 0.300
DBP (mmHg) 77.87 ± 7.08 77.21 ± 6.84 78.52 ± 7.28 0.169
Cholesterol (mg/dL) 207.10 ± 38.06 202.60 ± 36.19 211.52 ± 39.47 0.103
HDL-C level (mg/dL) 49.70 ± 16.79 52.15 ± 14.52 47.29 ± 18.50 0.001
Triglyceride (mg/dL) 149.63 ± 95.41 128.63 ± 84.27 170.27 ± 101.39 0.001
LDL (mg/dL) 139.97 ± 34.23 136.03 ± 33.30 143.84 ± 34.82 0.085
AST (IU/L) 24.95 ± 10.25 22.52 ± 9.90 27.35 ± 10.06 < 0.001
ALT (IU/L) 37.76 ± 35.36 29.92 ± 42.66 45.45 ± 24.11 < 0.001
Fasting glucose (mg/dL) 96.71 ± 27.87 91.68 ± 22.90 101.64 ± 31.33 0.002
BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; HDL: high density lipoprotein; LDL: low density 
lipoprotein; AST: aspartate aminotransferase; ALT: alanin transaminase
Table 2. NAFLD patients and non-NAFLD patients according to metabolic syndrome criteria
Disorder
Total (n = 228)
pNon-NAFLD  
(n = 113)
NAFLD  
(n = 115)
Obese 12 (10.62%) 36 (31.30%) 0.001
Hypertriglyceridemia 33 (29.20%) 57 (49.57%) 0.002
Low HDL-C 21 (18.58%) 31 (26.96%) 0.133
Hypertension 14 (12.39%) 23 (20.0%) 0.120
High glucose 7 (6.19%) 22 (19.13%) 0.006
Metabolic syndrome 2 (1.77%) 8 (7.0%) 0.056
  NAFLD: non-alcoholic fatty liver disease; HDL: high density lipoprotein
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= 0.001), more hypertriglyceridemia (49.57% vs 
29.20%; p = 0.002), and higher glucose levels (19.13% 
vs. 6.19%; p = 0.006). (Table 2). The prevalence of 
metabolic syndrome (more than 3 criteria) was 7% in 
NAFLD patients and 1.77% in non-NAFLD patients 
(p = 0.056).
The prevalence of NAFLD patients with normal 
BMI (< 25 kg/m2) was 39.13%. In the normal weight 
group, the prevalence of hypertriglyceridemia and 
high glucose levels were significantly more frequent 
in the NAFLD patients than in non-NAFLD patients. 
In the overweight and obese group (BMI > 25 kg/m2), 
the prevalence of hypertriglyceridemia, low HDL-C, 
hypertension, high glucose and metabolic syndrome 
were more frequent but not significant in NAFLD 
patients compared to non-NAFLD patients (Table 3). 
Table 4 showed the risk factors for NAFLD. Obesity 
was the strongest associated factor for NAFLD (95% 
CI = 1.87-7.85; OR = 3.83; p < 0.001), followed by 
high glucose levels (95% CI = 1.38-8.31; OR = 3.83; 
p = 0.008) and hypertriglyceridemia (95% CI = 1.38-
4.11; OR = 2.38; p = 0.002).
DISCUSSION
The reported prevalence of NAFLD varies widely 
depending on the population studied and the definition 
used. Fan et al reported that the prevalence of NAFLD 
in a general population of Shanghai, China was 
17.2%.8 In a study consisting of nearly 400 middle 
age individuals, the prevalence of NAFLD defined by 
USG was 46% and the prevalence of histologically 
confirmed NASH was 12.2%.9 The prevalence of 
NAFLD in those patients attending the routine health 
checkup was 22.6%.10 Generally, prevalence of 
NAFLD among the adult population of Asia-Pasific 
countries varied from 5% to 30%.11,12 In Indonesia the 
prevalence was 30%.13 In this study, we found that 
the prevalence of NAFLD was 7.9%. According to 
ultrasonography examination, degree of severity of 
fatty liver was classified into three categories: mild, 
moderate and severe. By this category, Martina et 
al reported the prevalence of NAFLD was 82.9%.14 
While in this study, the radiologist used severe criteria 
(marked increased in echogenicity, poor penetration of 
the of the posterior segment of the right hepatic lobe 
and poor or no visualization of the hepatic vessels and 
diaphragm) in diagnosis of NAFLD.14 
Mi ld  to  modera t e  e l eva t ion  o f  s e rum 
aminotransferases (ALT and AST) is the most common 
and often the only laboratory abnormality found in 
patients with NAFLD.15 In this study, patients with 
NAFLD showed elevation of transaminase enzyme, 
there were ALT 34.7% and AST 9.6%. Study by Fu et al 
showed that among 86 adolescents with fatty liver, only 
20 (23.3%) showed abnormality for ALT, however, 
there was an increasing trend of ALT abnormality as 
the severity of fatty liver increased.16
The association of NAFLD with obesity and 
metabolic syndrome are well established in both 
Caucasians and Asians. In our study the prevalence 
of normal BMI in NAFLD patients was 39%. This 
prevalence is higher than the other studies. Ekaterini 
et al showed that the prevalence of NAFLD patients 
with normal BMI was 12% and Deepa et al reported 
normal BMI was present in 21.7%.10,17 In our study 
the prevalence was 31.3% meanwhile the prevalence 
of NFLD in obese patients varied from 10–80%.11 
Radu et al reported that metabolic syndrome was 
found in 61.09% of patients with NAFLD and in the 
United States was 22% in the general population.18 
Central obesity is a mandatory condition for the 
metabolic syndrome. In patients with NAFLD had 
in percentage of central obesity, even in the presence 
Table 3. Prevalence of metabolic disorders according to body mass index
Characteristic
Normal weight
p
Over weight  and obese
pNon-NAFLD 
n = 56 (60.86%)
NAFLD
n = 36 (39.13%)
Non-NAFLD 
n = 57 (41.91%)
NAFLD
n = 79 (58.09%)
Hypertriglyceridemia 12 (21.43%) 19 (52.78%) 0.002 21 (36.84%) 38 (48.10%) 0.193
Low HDL-C 8 (14.29%) 8 (22.22%) 0.330 13 (22.80%) 23 (29.11%) 0.412
Hypertension 2 (3.57%) 5 (13.89%) 0.070 12 (21.05%) 18 (22.78%) 0.811
High glucose 2 (3.57%) 6 (16.67%) 0.030 5 (8.77%) 16 (20.25%) 0.069
Metabolic syndrome 0 (0%) 2 (5.56%) 0.076 2 (3.51%) 6 (7.59%) 0.319
NAFLD: non-alcoholic fatty liver disease; HDL: high density lipoprotein
Table 4. Risk factors for non-alcoholic fatty liver disease 
Risk factors Odds ratio 95% CI p
Obese 3.83 1.87–7.85 < 0.001
Hypertriglyceridemia 2.38 1.38–4.11 0.002
High glucose 3.38 1.38–8.31 0.008
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of normal weight.18 In our study the prevalence of 
metabolic syndrome in NAFLD patients was low (7%). 
Although the prevalence of metabolic syndrome was 
low, 49.57% of NAFLD patients fulfilled at least one 
criteria. Limitation of this study was that all patients 
who came for medical check up did not undergo 
waist circumference examination. According to the 
metabolic syndrome criteria there are five criteria; but 
in this study, waist circumference was not included 
and replaced by obese criteria (BMI > 30 kg/m2). This 
could be the reason why the prevalence of metabolic 
syndrome was lower compared to other studies. Xiaona 
et al showed in their study that metabolic factors could 
increase the risk of NAFLD up to 1.5 - 3.8 times.19 
In our study, obesity, hypertriglyceridemia, and high 
glucose levels were the risk factors for NAFLD. It 
is appropriate with the concept that in the majority 
of patients, NAFLD is associated with metabolic 
risk factors such as obesity, diabetes mellitus, and 
dyslipidemia.2
CONCLUSION
This study showed that the prevalence of NAFLD 
and metabolic syndrome patients in medical check 
up setting was lower than others study. It is better 
for clinicians to also give attention to normal 
weight patients, because the prevalence of NAFLD 
patients with normal BMI was quite high. Obesity, 
hypertriglyceridemia and high glucose levels were risk 
factors for NAFLD.
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